What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review.

Front Pharmacol · 2025 · PMC12375486 · PMID 40860888

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Additionally, osimertinib combined with bevacizumab (HR = 0.48; 95% CI: 0.23–1.01) showed a trend toward better PFS compared to osimertinib in patients with a smoking history.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

As a result, although there was a trend toward improved OS with the combination therapy, it did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.